{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037124","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2026-08-11T20:06:20+00:00","discovered_at":"2026-08-11T20:08:04.396064+00:00","generated_at":"2026-08-11T20:08:39.537597+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dermata to launch Tome Foundational Treatment on Aug 25, 2026; cash $4.4M","bullets":["Tome Foundational Treatment launch expected Aug 25, 2026; manufacturing and packaging complete.","Cash and equivalents $4.4M at June 30, 2026 vs $7.5M at Dec 31, 2025; sufficient into Q4 2026.","Q2 2026 R&D expenses $0.2M (down from $0.6M); SG&A $2.8M (up from $1.2M) on legal, marketing, compensation.","Second DTC product, an OTC acne treatment, planned after Foundational Treatment launch.","Company attended Be+Well Beauty and Wellness Show in June; began Tome social media campaign."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037124","json":"https://secwatch.observer/filing/0001493152-26-037124.json","markdown":"https://secwatch.observer/filing/0001493152-26-037124.md","text":"https://secwatch.observer/filing/0001493152-26-037124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226037124/0001493152-26-037124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226037124/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:08:39.537597+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}